title: Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006.
abstract: Alberta, Canada introduced the Streptococcus pneumoniae seven valent conjugate vaccine (PCV7) program for children less than 2 years of age in September 2002. We determined the rates of invasive pneumococcal disease in Alberta, Canada 2 years pre- and 4 years post-PCV7 introduction (2000-2006) as well as the rates of antibiotic resistance and serotype distribution in this same time period. Overall, PCV7 serotypes decreased 61% from 2000 to 2006. The greatest decrease in incidence of invasive pneumococcal disease occurred in children less than 2 years of age declining from a high of 96.7/100,000 (2000) to 25.8/100,000 (2006) (P<0.0001). Non-susceptibility of S. pneumoniae isolates to penicillin dropped significantly from 14% in 2000 to 4.6% in 2006 (P<0.0001). Non-susceptible erythromycin isolates also decreased from 8.8% (2000) to 5.8% (2006) (P=0.13). The introduction of PCV7 in Alberta, Canada has decreased the incidence of invasive pneumococcal disease in Alberta as well as resulting in a decrease in antibiotic resistance over this same time frame, principally for penicillin resistance.
authors.affiliation: The National Centre for Streptococcus, The Provincial Laboratory for Public Health (Microbiology), Edmonton, Canada. greg.tyrrell@capitalhealth.ca
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Tyrrell
authors.forename: Marguerite
authors.initials: M
authors.lastname: Lovgren
authors.forename: Natalie
authors.initials: N
authors.lastname: Chui
authors.forename: Jessica
authors.initials: J
authors.lastname: Minion
authors.forename: Sipi
authors.initials: S
authors.lastname: Garg
authors.forename: James D
authors.initials: JD
authors.lastname: Kellner
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Marrie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002170:Canada; D002648:Child; D002675:Child, Preschool; D004917:Erythromycin / Q000494:pharmacology; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007223:Infant; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010406:Penicillins / Q000494:pharmacology; D022242:Pneumococcal Vaccines / Q000276:immunology*; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000187:drug effects; D013997:Time Factors; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology
chemical_list: D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D010406:Penicillins; D022242:Pneumococcal Vaccines; D004917:Erythromycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination